Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 94,144 Shares

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 94,144 shares of Verona Pharma stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $4.39, for a total value of $413,292.16. Following the completion of the sale, the chief executive officer now directly owns 15,204,752 shares in the company, valued at $66,748,861.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

David Zaccardelli also recently made the following trade(s):

• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $1,076,533.92.

Verona Pharma Price Performance

Shares of NASDAQ:VRNA opened at $38.39 on Wednesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 8.61 and a current ratio of 8.61. Verona Pharma plc has a 52-week low of $11.39 and a 52-week high of $39.40. The stock’s fifty day simple moving average is $31.07 and its 200-day simple moving average is $22.49.

Verona Pharma (NASDAQ:VRNA) last released its earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). The business had revenue of $5.62 million for the quarter, compared to the consensus estimate of $2.31 million. During the same quarter last year, the business posted ($0.18) EPS. On average, research analysts predict that Verona Pharma plc will post -2.07 EPS for the current year.

Institutional Trading of Verona Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC acquired a new stake in shares of Verona Pharma during the second quarter worth $29,000. EMC Capital Management acquired a new stake in Verona Pharma in the 2nd quarter worth about $38,000. GAMMA Investing LLC grew its holdings in Verona Pharma by 70.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock valued at $38,000 after buying an additional 553 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Verona Pharma by 25.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after buying an additional 529 shares during the period. Finally, Legato Capital Management LLC acquired a new position in shares of Verona Pharma during the 2nd quarter valued at about $154,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on VRNA. Wells Fargo & Company boosted their price target on Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a research note on Tuesday. Truist Financial boosted their target price on Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Canaccord Genuity Group lifted their price target on Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, HC Wainwright increased their price objective on shares of Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Verona Pharma presently has an average rating of “Buy” and a consensus target price of $43.83.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.